Your first 90 days
Your first 90 days on Besremi for polycythemia vera
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Besremi is an interferon shot given every 2 weeks, and PharmaEssentia describes it as an at-home treatment. Before the first carton arrives, the hematologist's office usually sends an enrollment form and the insurance plan reviews the prescription. Baseline blood tests come first, with a pregnancy test where it applies. After that come blood counts every 2 weeks while the dose is raised in small steps. This page lays out those first 3 months from the FDA label, PharmaEssentia's support program and one insurer's published policy.
What has to happen before the first bottle ships
Besremi's label names no REMS safety program, so the first carton waits on baseline tests, an insurance approval, a specialty pharmacy and injection training. These are the 9 things in the way, in order.
Who the label says must not use Besremi
The label lists 5 groups, starting with anyone who has or had a severe psychiatric disorder, particularly severe depression, suicidal thoughts or a suicide attempt.
- The second group is people allergic to interferons, including interferon alfa-2b, or to any inactive ingredient in Besremi.
- The third is people with moderate or severe liver impairment, which doctors call Child-Pugh B or C. The fourth is people with a history or presence of active serious or untreated autoimmune disease.
- The fifth is transplant recipients who take medicines that suppress the immune system.
- The Medication Guide also asks you to tell your healthcare provider about past mental illness treatment, thyroid problems and diabetes.
- Its list also has heart problems, bleeding problems, blood clots, liver problems, kidney problems and conditions that suppress the immune system.FDA label
Heart and kidney conditions the label says to avoid
The label says to avoid Besremi in severe or unstable heart and blood vessel disease.
- Its examples are uncontrolled high blood pressure, congestive heart failure, a serious abnormal heart rhythm, significant narrowing of the heart's arteries and unstable angina.
- A recent stroke or heart attack is on the same list.
- The label also says to avoid Besremi when kidney function, measured as eGFR, is below 30mL/min.
- The label also says not to use Besremi in active serious or untreated hormone gland disorders linked to autoimmune disease.FDA label
A pregnancy test, where it applies
The label calls for a pregnancy test before treatment for anyone who can become pregnant.
- It says Besremi can harm an unborn baby and can cause miscarriage.
- Effective birth control is advised during treatment and for at least 8 weeks after the final dose.
- The label says not to breastfeed during treatment and for 8 weeks after the final dose.FDA label
Baseline blood tests
The label calls for a complete blood count before treatment starts.
- It also calls for liver enzymes and liver function, triglycerides and serum creatinine, a kidney test, at baseline.
- The same tests are repeated during treatment, so these first results become the comparison point.FDA label
An eye exam
The label advises patients to have eye exams before and during Besremi treatment.
- It singles out people with a condition linked to retina damage, such as diabetes or high blood pressure.
- The Medication Guide says you should have an eye exam before and during treatment if you have either one.FDA label
A full list of medicines and supplements
The Medication Guide asks you to tell your healthcare provider about every prescription and over-the-counter medicine, vitamin and herbal supplement.
- The label says to avoid Besremi with medicines that suppress the bone marrow and with narcotics, hypnotics or sedatives.
- Patients who receive either combination are monitored for added effects.
- Hydroxyurea is handled by its own schedule in the label, with a taper during weeks 3 to 12.FDA label
Training before the first injection
The label says the prescriber first confirms that you or a caregiver are an appropriate candidate to give the injection.
- Training on storage, preparation and injection technique should then be provided.
- The Medication Guide says not to inject yourself until your healthcare provider has shown you the right way.
- If home injection is not appropriate for any reason, the label says a healthcare professional should give Besremi.FDA label
The enrollment form and the insurance check
PharmaEssentia SOURCE lists 2 ways to enroll, a call to 800-700-5053 or a form.
- With the form, you sign your part, your doctor signs theirs, and the doctor faxes it to 800-700-5065.
- A SOURCE Case Manager then calls you to discuss the next steps.PharmaEssentia SOURCE
Which pharmacy ships it
PharmaEssentia says Besremi is filled through specialty pharmacy partners, including Biologics and Onco360, and shipped directly to the patient.
- Some offices can dispense it themselves if they are eligible GPO members or authorized health system pharmacies.
- The SOURCE enrollment form includes a section that serves as the first prescription, the company's page for offices says.SOURCE delivery, for offices
The days that matter
Counted from the first injection, with a dose every 2 weeks and a blood count every 2 weeks while the dose is being raised. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Enrollment and insurance check
You call PharmaEssentia SOURCE or your doctor's office faxes the enrollment form.
- SOURCE then contacts your insurance company and calls you to discuss next steps.
Baseline blood tests and pregnancy test
The label calls for a complete blood count, liver tests, triglycerides and serum creatinine before the first dose.
- A pregnancy test is done first for anyone who can become pregnant.
Eye exam
The label advises an eye exam before treatment, especially for people with diabetes or high blood pressure.
- The label advises more eye exams during treatment, and prompt checks of any eye symptoms.
Injection training
The label says training on storage, preparation and injection technique should be provided before you or a caregiver give Besremi.
- Ask the office who will teach you and which device you will use, the syringe or the pen.
Welcome Kit
PharmaEssentia says you receive a Welcome Kit once you are ready to begin treatment.
- It includes the Instructions for Use, a placemat showing the materials you need and a treatment tracker notepad.
First injection
The label's starting dose is 100mcg, or 50mcg for people who are also taking hydroxyurea.
- Under the label, the carton rests at room temperature for 15 to 30 minutes first.
- The injection goes under the skin of the lower belly or the top of the thigh.
Blood count, and the dose may go up
The label calls for a complete blood count every 2 weeks during the titration phase, when the dose is being raised.
- Under the label, the dose goes up by 50mcg every 2 weeks until blood counts are stable.
Hydroxyurea taper, if you were taking it
For people moving from hydroxyurea, the label has the prescriber lower the total 2-week hydroxyurea dose gradually.
- The reduction is 20% to 40% every 2 weeks during weeks 3 to 12.
Blood count, number 2
Next delivery
PharmaEssentia says SOURCE assists with delivery so the prescription arrives at your door each month.
- Ask the pharmacy how many cartons come in each shipment and when the next one ships.
Blood count, number 3
Blood count, number 4
Blood count, number 5
Blood count, number 6
Hydroxyurea ends, if you were tapering
For people who moved over from hydroxyurea, the label says to discontinue hydroxyurea by week 13.
- Besremi dose steps of 50mcg every 2 weeks continue until blood counts are stable.
Still early by the study's measure
In PEGINVERA, the label's polycythemia vera study, 61% of patients reached a complete hematological response.
- Among those patients, the median time to that response was 7.8 months.
- Three months in, the hematologist may still be raising the dose and checking blood counts every 2 weeks.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Besremi label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated August 25, 2026, read from the FDA's label database today. FDA label
- August 2026
The August 2026 label lists changes to the dosing sections and to 7 warnings. The changed warnings cover depression and suicide, hormone problems, heart problems, blood counts, eyes, blood fats and the liver.FDA label
- June 2026
The label dates its change to the preparation and administration section to June 2026. That section now gives separate steps for the prefilled syringe and the prefilled pen.FDA label
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- Every 2 weeks, at the dose your hematologist sets
The label's dose rises in 50mcg steps every 2 weeks, up to a maximum of 500mcg, until blood counts are stable.
- The Medication Guide says not to inject more than your prescribed dose.
- It also says not to inject more than 1 dose every 2 weeks without talking to your healthcare provider.FDA label
- What stable blood counts means
The label's target is a hematocrit below 45%, platelets below 400 x 10⁹/L and white blood cells below 10 x 10⁹/L. Phlebotomy may still be needed as a rescue treatment while the dose is being raised, the label says.
- After a dose reduction and recovery, the label lets the prescriber consider raising the dose again if counts are not controlled.FDA label
- Measuring a dose with the prefilled syringe
Each syringe holds 500mcg, which can be more than your prescribed dose, and its dose lines are 50mcg apart.
- Under the Instructions for Use, you hold the syringe at eye level with the needle pointing straight up.
- You then slowly push the plunger until the top edge of the gray stopper lines up with your dose.
- The extra medicine goes onto a paper towel or into a sink or trash can.
- If too much is removed, the instructions say not to inject and to contact your healthcare provider or pharmacist.FDA label
- Setting a dose with the pen
The Besremi Pen also contains 500mcg and dials in 50mcg steps.
- Its instructions start with a flow check, which is dialing to the drop symbol and pressing the button, done 4 times.
- The check can be repeated up to 3 more times until liquid shows at the needle tip.
- If liquid still does not show after 7 cycles in total, the instructions say to get a new Besremi Pen carton and start over.
- You then dial your prescribed dose, press and hold the button, and count to 5 after the window returns to 0.
- Liquid left in the pen after the injection is normal, the instructions say.FDA label
- Where to inject
The sites are the lower belly, at least 2 inches from the belly button, or the top of the thighs.
- The label says to change the site for each injection.
- It also says not to inject into skin that is irritated, red, bruised, infected or scarred.FDA label
- One use only
The syringe and the pen are each for one injection and are never reused.
- The instructions say to throw the device away right after use, even if medicine is left inside.
- It goes into an FDA-cleared sharps disposal container with the needle still attached.
- A heavy-duty plastic household container with a tight, puncture-resistant lid is the alternative the instructions describe.FDA label
- Storage
The label says to store Besremi in the refrigerator at 36 to 46 degrees Fahrenheit, in the original carton to protect it from light.
- It must not be frozen, and a syringe that was frozen or left in direct sunlight should not be used.
- Before an injection, the carton sits flat at room temperature for 15 to 30 minutes.
- The instructions say not to warm it any other way.FDA label
- Check the liquid
The liquid should be clear and colorless to slightly yellow, with no particles.
- The label says not to use a syringe or pen if the liquid is cloudy or discolored, or if the device looks damaged.
- The expiration date on the carton is checked before each injection.FDA label
- Driving and machinery
The label says Besremi may affect the ability to drive and use machinery.
- Patients should not drive or use heavy machinery until they know how Besremi affects them.
- Anyone who has dizziness, sleepiness or hallucinations during treatment should avoid driving or using machinery, the label says.FDA label
- Pregnancy and breastfeeding
The Medication Guide says Besremi can harm an unborn baby and can cause loss of a pregnancy.
- It says to tell your healthcare provider if you become pregnant during treatment.
- Besremi can also affect menstrual cycles and may cause periods to stop.
- Breastfeeding is not advised during treatment and for 8 weeks after the final dose.FDA label
- Teeth, eyes and regular checks
The Medication Guide says to brush and floss well and to get regular dental exams during treatment.
- Besremi can cause tooth and gum problems that can lead to tooth loss, and dry mouth over long-term treatment.
- Blood tests continue regularly so the healthcare provider can monitor the disease and check for side effects.FDA label
- If you inject too much
The Medication Guide says to call the Poison Help Line at 1-800-222-1222 or your healthcare provider right away.
- The label says an overdose may cause flu-like symptoms or other side effects, and that there is no antidote.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Thoughts of suicide, depression and mood changes
The Medication Guide says to stop using Besremi right away if you have thoughts of hurting yourself or thoughts of suicide.
- You, a caregiver or a family member should tell your healthcare provider or get medical help right away for the signs below.
- They are thoughts about suicide or dying, suicide attempts, new or worse depression, and new or worse anxiety.
- The list also has panic attacks, feeling very agitated or restless, trouble sleeping, and new or worse irritability.
- It ends with acting aggressive, angry or violent, acting on dangerous impulses, and an extreme increase in activity or talking.
- Any other unusual change in behavior or mood counts too, and these problems can appear after the last dose.FDA label
Serious allergic reactions
The Medication Guide says to stop using Besremi and get medical help right away for signs of a serious allergic reaction.
- The signs are skin rash or hives, itching, and swelling of your face, eyes, lips, tongue or throat.
- Trouble breathing, chest pain, and feeling dizzy or faint are on the same list.FDA label
Heart, blood vessel and blood clot signs
The Medication Guide says to tell your healthcare provider right away about any of these signs.
- They include a fast heart rate or abnormal heartbeat, trouble breathing or chest pain, and tiredness.
- Pain, swelling or redness in the arms, legs, ankles or feet is on the list.
- The rest are sudden confusion, numbness or weakness, loss of coordination, trouble speaking clearly and sudden vision changes.FDA label
Low blood counts, bleeding and infection
The Medication Guide says to tell your healthcare provider or get medical help right away for these symptoms.
- They are weakness and tiredness, bruising easily, frequent nosebleeds, gum or tongue bleeding, and bleeding in the eye.
- Fever, chills, burning and painful urination, urinating often, and coughing up yellow or pink mucus are also listed.
- In the label's polycythemia vera studies, infection occurred in 48% of patients and serious infection in 8%.FDA label
Autoimmune, thyroid and blood sugar problems
Besremi may cause autoimmune problems, including thyroid problems, high blood sugar and type 1 diabetes.
- The Medication Guide says to tell your healthcare provider right away about tiredness, urinating more often than normal, or being very thirsty.
- Other listed symptoms are an increase in appetite, problems concentrating, sensitivity to heat or cold, weight changes and skin changes.FDA label
Pancreas and intestine
For pancreatitis, the Medication Guide lists nausea, vomiting, pain in the upper stomach area, bloating and fever.
- For colitis, it lists stomach area pain, bloody diarrhea or blood in your stool, and fever.
- The Medication Guide says to tell your healthcare provider if you develop any of these signs.
- The label notes that colitis has appeared as early as 12 weeks after starting interferon alfa products.FDA label
Lungs and eyes
The Medication Guide says to tell your healthcare provider about shortness of breath, cough or difficulty breathing.
- For the eyes, it lists blurred vision, dry eyes, seeing floaters or flashes of light, and eye pain or redness.
- Sudden loss of vision is on the same list, because severe retina problems can lead to blindness.FDA label
Liver and kidneys
Liver signs in the Medication Guide start with yellowing of the skin or the whites of the eyes.
- Swelling, pain or discomfort in the stomach area, confusion, sleepiness and nausea are also liver signs.
- The liver list ends with loss of appetite, tiredness, diarrhea and bleeding more easily than normal.
- Kidney signs are changes in the amount or color of urine, blood in the urine, ankle swelling and loss of appetite.FDA label
Skin and blood fats
The Medication Guide says to get medical help if you develop signs of a skin problem during treatment.
- Its list is itching, hair loss, rash, redness, dry skin, red scaly patches called psoriasis, and acne.
- Thickening of the skin and excessive sweating complete that list.
- Besremi can also raise cholesterol and triglycerides, which are followed with blood tests and may be treated.FDA label
Common side effects in polycythemia vera
The most common in the label's PEGINVERA study were flu-like illness (59%), joint pain (47%), tiredness (47%) and itching (45%).
- Sore throat or cold symptoms (43%) and muscle and bone pain (41%) followed.
- Depression was reported in 20% of patients, and 8% stopped treatment because of it.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization not yet filedPharmaEssentia SOURCE coordinates with your insurance company to find out whether a prior authorization is required. It helps the office learn the submission process and any extra documents, and the office submits the request. After that, SOURCE is available to help the office monitor the status of the request.SOURCE access, for offices
- The diagnosis is not on the requestUnitedHealthcare's public policy, effective December 1, 2025, approves Besremi on one criterion, a diagnosis of polycythemia vera. Other plans set their own rules, so the office confirms what your plan asks for.UnitedHealthcare policy
- A supply limit or step therapy ruleThe UnitedHealthcare policy says supply limits or step therapy may be in place under some plans. Your hematologist's office can ask the plan which rule applied and what it needs to review it.UnitedHealthcare policy
- A denial, or Besremi is not on the plan's drug listSOURCE can work with the office to identify the steps needed to appeal the plan's decision. PharmaEssentia offers the office sample letters of medical necessity, appeal and formulary exception.SOURCE access, for offices
- The enrollment form is missing informationPharmaEssentia says a Case Manager may follow up with you or your doctor to complete the enrollment. The company says complete and accurate enrollment details help SOURCE begin the process right away.SOURCE enrollment
- The prescription went to a pharmacy that cannot fill itPharmaEssentia names specialty pharmacy partners, including Biologics and Onco360, that ship Besremi directly to patients. Offices with questions about pharmacy qualifications can call SOURCE at 800-700-5053.SOURCE delivery, for offices
- A copay you cannot payWith commercial insurance that covers Besremi, the Copay and Coinsurance Assistance Program may lower the cost to as little as $0 per month. You must live in the United States or a US territory and have a valid prescription from a US physician.SOURCE financial help
- Medicare, Medicaid, TRICARE or Veterans Health coverageThe copay program is not available to people whose prescription coverage comes from any federal or state healthcare program. SOURCE says it will work with you to identify organizations that may help with treatment-related costs.SOURCE financial help
- No insurance, or the plan does not cover BesremiPharmaEssentia's Patient Assistance Program offers Besremi at no cost to eligible people, including those without insurance. You must also meet its financial eligibility criteria, and restrictions apply.SOURCE financial help
- An approval delay or a gap in coverageSOURCE can check whether you are eligible for a temporary supply of Besremi during an insurance approval delay or a coverage gap. PharmaEssentia says restrictions apply to the temporary supply and are subject to change.SOURCE getting started
UnitedHealthcare prior authorization policy, effective December 1, 2025
- A diagnosis of polycythemia vera
- Or a use that the NCCN Drugs and Biologics Compendium recognizes with a category of evidence and consensus of 1, 2A or 2B
Approval length. 12 months.
This policy took effect on December 1, 2025, and cites the April 2024 package insert. It predates the 2026 label changes, which added the Besremi Pen in June and essential thrombocythemia in August, so it does not mention either. The policy says supply limits or step therapy may be in place, and that state mandates and the member's own plan can change the criteria. Other insurers set their own rules, which may differ from this example. UnitedHealthcare policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- A Case Manager who answers questions, explains your insurance coverage and helps find resources for financial support
- A SOURCE Nurse who can walk you through the injection step by step, with refreshers at any time during treatment SOURCE getting started
- A Welcome Kit with the Instructions for Use, a supplies placemat and a treatment tracker with reminder stickers SOURCE enrollment
- Copay help with commercial insurance that covers Besremi, as little as $0 per month if eligible, not for Medicare, Medicaid, TRICARE, Veterans Health or other government plans SOURCE financial help
- The copay offer is also not valid for cash-paying patients or where the plan reimburses the entire cost of Besremi SOURCE financial help
- A Patient Assistance Program, Besremi at no cost for eligible people with no prescription coverage or whose insurance does not cover it SOURCE financial help
- A possible temporary supply during an insurance approval delay or a gap in coverage, with restrictions SOURCE getting started
- Help with delivery of the prescription directly to your door each month SOURCE getting started
Details as the drugmaker publishes them. PharmaEssentia SOURCE
Five questions for the pharmacist or the support line
- Which specialty pharmacy are you, and what number will the delivery call come from?
- Am I getting the prefilled syringe or the Besremi Pen, and are the right Instructions for Use in the box?
- How many cartons come in each shipment, and how is the box kept cold on the way?
- My dose changes every 2 weeks for now. Does the prescription you hold show my current dose?
- Do you supply alcohol swabs and a sharps disposal container, or do I get them myself?
Questions people ask in the first weeks
How long does it take to get Besremi after it is prescribed?
There is no fixed number of days between the prescription and the first dose. PharmaEssentia SOURCE contacts your insurance company after enrollment, and a prior authorization takes as long as the plan takes. Baseline blood tests and injection training also come before the first dose.
What is the starting dose of Besremi for polycythemia vera?
The label's starting dose is 100mcg under the skin every 2 weeks. For people already taking hydroxyurea it is 50mcg, given alongside hydroxyurea. The dose can rise by 50mcg every 2 weeks, up to 500mcg, until blood counts are stable.
What happens to hydroxyurea when Besremi starts?
The label has the prescriber taper hydroxyurea gradually while the Besremi dose rises. The total 2-week hydroxyurea dose is reduced by 20% to 40% every 2 weeks during weeks 3 to 12. Under the label, hydroxyurea is discontinued by week 13 of Besremi treatment.
Do I inject Besremi myself?
You, a caregiver or a healthcare professional can give it. The label says the prescriber decides whether home injection is appropriate, and training comes first. If it is not appropriate for any reason, a healthcare professional gives the injection.
Why does the syringe hold more than my dose?
Every Besremi syringe and pen contains 500mcg, the label's maximum dose. With the syringe, the extra medicine is pushed out until the gray stopper lines up with your dose. With the pen, you dial your dose in 50mcg steps, and leftover liquid is thrown away with the pen.
How often are blood tests needed on Besremi?
The label calls for a complete blood count every 2 weeks while the dose is being raised or changed. Once the best dose is established, the count is checked every 3 to 6 months, or more often if needed. Liver tests, triglycerides and kidney function are also checked before and during treatment.
Can Besremi be given every 4 weeks?
The label does not allow that in the first year of stable counts. The 2-week schedule is kept for at least 1 year after blood counts become stable. After that year on a stable dose, the label says the prescriber may stretch the interval to every 4 weeks.
What if I miss a dose of Besremi?
The label and the Medication Guide do not give a schedule for missed doses. The Medication Guide says not to inject more than 1 dose every 2 weeks without talking to your healthcare provider. Your hematologist's office can tell you when to give the next injection.
Does Besremi have a boxed warning or a REMS?
Besremi has a boxed warning, which is the strongest kind the FDA uses. It says interferon alfa products may cause or worsen fatal or life-threatening neuropsychiatric, autoimmune, ischemic and infectious disorders. The label and the FDA's 2026 approval letters do not mention a REMS safety program.
Free email alert
Hear when the Besremi label changes
One email the day the FDA revises the Besremi label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Besremi only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Polycythemia vera for new trials, FDA decisions and label changes for every treatment.
Sources
- BESREMi (ropeginterferon alfa-2b-njft) injection, for subcutaneous use, prescribing information, Medication Guide and Instructions for Use, Revised 8/2026, PharmaEssentia USA, via DailyMed and openFDA, August 25, 2026.
- BLA 761166/S-013 supplement approval, Besremi (ropeginterferon alfa-2b-njft) injection, new indication for essential thrombocythemia, FDA, August 28, 2026.
- BLA 761166/S-010 supplement approval, Besremi (ropeginterferon alfa-2b-njft) injection, new single-dose prefilled pen injector, FDA, June 25, 2026.
- BESREMi® (ropeginterferon alfa-2b-njft) Patient Support, PharmaEssentia, November 12, 2026.
- How Do I Get Started With PharmaEssentia SOURCE™?, PharmaEssentia, November 12, 2026.
- Getting Started on BESREMi® (ropeginterferon alfa-2b-njft), PharmaEssentia, November 12, 2026.
- Financial Assistance for BESREMi® (ropeginterferon alfa-2b-njft), PharmaEssentia, November 12, 2026.
- PharmaEssentia SOURCE™: Access & Reimbursement Support, PharmaEssentia, November 12, 2026.
- How to Prescribe BESREMi® (ropeginterferon alfa-2b-njft), PharmaEssentia, November 12, 2026.
- Besremi® (ropeginterferon alfa-2b-njft), Prior Authorization/Notification, Program Number 2025 P 1048-16, UnitedHealthcare Pharmacy, Clinical Pharmacy Programs, December 1, 2025.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing hematologist. Found an error? Use the report link in the footer and it will be checked against the source.